Tarsus Pharmaceuticals, Inc.
TARS
Classifica tra le azioni
#4708
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prezzo delle azioni
$68.50
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$3.21B
Variazione (1 giorno)
-3.51%
Variazione (1 anno)
-6.07%
Paese
US
Scambia Tarsus Pharmaceuticals, Inc. (TARS)
Categoria
Healthcare
EPS per Tarsus Pharmaceuticals, Inc. (TARS)
EPS al June 2026 TTM: $-1.09
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Tarsus Pharmaceuticals, Inc., l’EPS attuale della società (TTM) è $-1.09. Alla fine del 2023, la società aveva un EPS di $-4.62 un aumento rispetto a rispetto a quello del 2022, che era di $-2.52.
Storico EPS per Tarsus Pharmaceuticals, Inc. da 2018 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
